Treatment of @entity995 with XXXX and @entity3003 .

@entity1 @entity3003 @entity2879 @entity1442 @entity1891 @entity995
PURPOSE: To evaluate the efficacy of chemoreduction using @entity1891 and @entity3003 in preventing or delaying external-beam radiotherapy (EBRT) or enucleation in @entity1 with @entity995 . @entity1 AND METHODS: Twenty-five @entity1 (43 eyes) with newly diagnosed @entity995 received primary treatment with eight courses of @entity1891 and @entity3003 . Focal treatments were delayed until documentation of disease progression. Outcome measures for each eye were length of time to disease progression, avoidance or delay of EBRT, and globe survival. Event-free survival was defined as the length of time to EBRT or enucleation. RESULTS: Disease in all eyes responded to chemotherapy and progressed in only two @entity1 before completion of the eight courses of therapy. Disease in all but four eyes progressed and required focal treatments. Event-free survival estimates at 2 years were 59.2% +/- 12.0% for Reese-Ellsworth group I, II, and III eyes and 26.3% +/- 9.2% for group IV and V eyes. Nineteen eyes (44.2%) required EBRT and 13 eyes (30.2%) were enucleated. The ocular salvage rate was 83.3% for Reese-Ellsworth group I to III eyes and 52.6% for group IV and V eyes. For those @entity1 receiving EBRT, the median time from enrollment to EBRT was 9.5 months (median age at EBRT, 21 months). CONCLUSION: In combination with appropriate early intensive focal treatments, chemoreduction with @entity1891 and @entity3003 , without @entity2879 , may be an alternative treatment for @entity1 with early-stage @entity995 , although additional studies are needed. @entity1 with @entity1442 require more aggressive treatments.
